Boston Scientific has introduced the Promus Element Everolimus-Eluting Coronary Stent System and Taxus Element Paclitaxel-Eluting Coronary Stent System in India.
Both Element Systems incorporate the same novel platinum chromium (PtCr) alloy, stent design and advanced catheter delivery system, and represent the company’s third-generation drug-eluting stent (DES) technology.
The PtCr Element Stent series offer greater radial strength, flexibility and visibility while reducing stent recoil.
The stent geometry helps to create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system.
Boston Scientific president and CEO Ray Elliott said the key component of their growth strategy involves expanding their footprint in emerging markets like India, where they are making significant investments in sales, distribution and clinical infrastructure.
The Promus Element Stent is being evaluated in the Platinum clinical trial, which completed enrollment of 1,532 patients in September 2009 at more than 140 sites worldwide.
The Taxus Element Stent is being evaluated in the Perseus trial, which reported 12-month results in March 2009, demonstrating positive safety and efficacy outcomes in workhorse lesions for the Taxus Element Stent System compared to the Taxus Express2 Stent System